Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Catherine M Claussen, MS, Tammy Chuang, Jatin Shah, MD, Hans Lee, MD, Nina Shah, MD, Krina K Patel, Qaiser Bashir, MD, Simrit Parmar, MD, Sheeba Thomas, MD, Muzaffar Qazilbash, MD, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Donna Weber, MD, Robert Z. Orlowski, PhD, MD, Lei Feng, MS, Elisabet E. Manasanch, MD

Blood (2015) 126 (23): 5390.

https://doi.org/10.1182/blood.V126.23.5390.5390

Published: 2015

Journal Articles

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, MD, Lei Feng, MS, Sheeba K. Thomas, MD, Donna Weber, MD, Michael Wang, MD, Elisabet E. Manasanch, MD, Kathleen Mendoza, RN, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 376.

https://doi.org/10.1182/blood.V126.23.376.376

Published: 2015

Journal Articles

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Donna Weber, MD, Sheeba K Thomas, MD, Michael Wang, MD, Francesco Turturro, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Qaiser Bashir, MD, Uday R. Popat, MD, Elisabet E. Manasanch, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Yago Nieto, MD PhD, Richard E. Champlin, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 3155.

https://doi.org/10.1182/blood.V126.23.3155.3155

Published: 2015

Journal Articles

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Koji Sasaki, MD, Nina Shah, MD, Qaiser Bashir, MD, Chitra M. Hosing, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Simrit Parmar, MD, Jatin J. Shah, MD, Donna Weber, MD, Daniel Weissinger, Sheeba K. Thomas, MD, Robert Z. Orlowski, MD PhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2015) 126 (23): 3194.

https://doi.org/10.1182/blood.V126.23.3194.3194

Published: 2015

Journal Articles

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

Jatin J. Shah, MD, Lei Feng, MS, Elisabet E. Manasanch, MD, Donna Weber, MD, Sheeba K Thomas, MD, Francesco Turturro, MD, Nina Shah, MD, Uday R. Popat, MD, Yago Nieto, MD PhD, Qaiser Bashir, MD, Silvia C Munoz, RN, Ashley Landry, RN, Kathleen Mendoza, RN, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 187.

https://doi.org/10.1182/blood.V126.23.187.187

Published: 2015

Journal Articles

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

Paul G. Richardson, MD, Melissa Alsina, MD, Donna Weber, MD, Steven E. Coutre, MD, Sagar Lonial, MD, Cristina Gasparetto, MD, Sutapa Mukhopadhyay, PhD, Michael Ondovik, PharmD, MBA, Mahmudul Khan, PhD, Carole Paley, MD, Robert Schlossman, MD

Blood (2012) 120 (21): 1852.

https://doi.org/10.1182/blood.V120.21.1852.1852

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Sagar Lonial, MD, Adam Cohen, Jeffrey Zonder, MD, William I Benzinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, MD, PhD, R. Donald Harvey, PharmD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Duncan Walker, PhD, Brandi Hilder, PhD, Ann Ptaszynski, Jatin J Shah, MD

Blood (2011) 118 (21): 2935.

https://doi.org/10.1182/blood.V118.21.2935.2935

Published: 2011

Journal Articles

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Jatin J Shah, MD, Jeffrey Zonder, MD, Adam Cohen, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D., Sheeba K Thomas, M.D., Donna Weber, MD, Jonathan L. Kaufman, MD, R. Donald Harvey, PharmD, Duncan Walker, PhD, Kevin Litwiler, PhD, Sharon Karan, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1860.

https://doi.org/10.1182/blood.V118.21.1860.1860

Published: 2011

Journal Articles

Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis

Simrit Parmar, MD, Mubeen Khan, Gabriela Rondon, MD, Nina Shah, MD, Qaiser Bashir, MD, Shawndeep Tung, MD, Jatin J Shah, MD, Donna Weber, MD, Robert Z. Orlowski, MD, PhD, Sergio Giralt, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2010) 116 (21): 2400.

https://doi.org/10.1182/blood.V116.21.2400.2400

Published: 2010

Journal Articles

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, MD, Michael Wang, MD, Sheeba Thomas, MD, Muzaffar H. Qazilbash, MD, Simrit Parmar, M.D., Nina Shah, MD, Qaiser Bashir, MD, Uday Popat, MD, Donna Weber, MD

Blood (2010) 116 (21): 1948.

https://doi.org/10.1182/blood.V116.21.1948.1948

Published: 2010

Journal Articles

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Paul Richardson, MD, Donna Weber, MD, Constantine S. Mitsiades, MD, PhD, Meletios A. Dimopoulos, MD, Jean-Luc Harousseau, MD, Jennifer Houp, Thorsten Graef, MD, PhD, Christine K Gause, Catriona Byrne, Kenneth C. Anderson, MD, David Siegel, MD, PhD

Blood (2010) 116 (21): 1951.

https://doi.org/10.1182/blood.V116.21.1951.1951

Published: 2010

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.

Qaiser Bashir, MD, Wei Wei, Alexandre Chiattone, MD, Gabriela Rondon, MD, Simrit Parmar, M.D., Nina Shah, MD, Ernesto Harold Booc, Dinh Yvonne, Qureshi Sofia, Jatin J Shah, MD, Robert Z. Orlowski, MD, PhD, Donna Weber, MD, Richard Champlin, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2010) 116 (21): 4569.

https://doi.org/10.1182/blood.V116.21.4569.4569

Published: 2010

Journal Articles

High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

Simrit Parmar, M.D., Mubeen Khan, Gabriela Rondon, MD, Nina Shah, MD, Qaiser Bashir, MD, Shawndeep Tung, MD, Jatin J Shah, MD, Donna Weber, MD, Robert Z. Orlowski, MD, PhD, Sergio Giralt, MD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2010) 116 (21): 1350.

https://doi.org/10.1182/blood.V116.21.1350.1350

Published: 2010

Journal Articles

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Jatin J Shah, MD, Jeffrey A. Zonder, MD, Adam Cohen, Donna Weber, MD, Sheeba Thomas, MD, Michael Wang, MD, Jonathan L. Kaufman, MD, Steven Michael Burt, Duncan Walker, Burgess Freeman, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski, MD, PhD, Sagar Lonial, MD

Blood (2010) 116 (21): 1959.

https://doi.org/10.1182/blood.V116.21.1959.1959

Published: 2010

Journal Articles

Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.

Blood (2010) 116 (21): 4576.

https://doi.org/10.1182/blood.V116.21.4576.4576

Published: 2010

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Manish Sharma, MD, Peter Thall, PhD, Xuemei Wang, PhD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Eric Han, MD, Michael Wang, MD, Donna Weber, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 2309.

https://doi.org/10.1182/blood.V114.22.2309.2309

Published: 2009

Journal Articles

Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.

Meletios A Dimopoulos, Mohamad Hussein, Arlene S. Swern, Donna Weber

Blood (2009) 114 (22): 2874.

https://doi.org/10.1182/blood.V114.22.2874.2874

Published: 2009

Journal Articles

Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.

Sagar Lonial, Rachid Baz, Arlene S. Swern, Donna Weber, Meletios A. Dimopoulos

Blood (2009) 114 (22): 2879.

https://doi.org/10.1182/blood.V114.22.2879.2879

Published: 2009

Journal Articles

Curability of Multiple Myeloma.

Kay B Delasalle, BS, Luhua Wang, MD, Donna Weber, MD, Sergio A. Giralt, MD, Sheeba Thomas, MD, Jatin Shah, MD, Beverly Handy, MD, Robert Z. Orlowski, MD, PhD, Raymond Alexanian, M.D.

Blood (2009) 114 (22): 3864.

https://doi.org/10.1182/blood.V114.22.3864.3864

Published: 2009

Journal Articles

The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma.

Sundar Jagannath, MD, Donna Weber, MD, Ronald Sobecks, Gary J Schiller, Lisa Lupinacci, David Reiser, Judith Allen, Syed Rizvi

Blood (2009) 114 (22): 3886.

https://doi.org/10.1182/blood.V114.22.3886.3886

Published: 2009

NARROW

Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant

Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study

Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis

Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma

A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.

High Dose Melphalan with Autologous Stem Cell Transplantation Overcomes Poor Prognosis of Primary Amyloidosis

A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma

Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.

Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.

Curability of Multiple Myeloma.

The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only